Plain-English translation of NCT06503224 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called SCAR02, which is a type of cell therapy made from your own immune cells. Researchers have modified these cells in the lab to help fight the immune system's attack on your body. This study aims to see if SCAR02 is safe and effective for people with autoimmune diseases — like rheumatoid arthritis or lupus — that have not improved with standard medications.
Many people with serious autoimmune diseases don't get better with current treatments and continue to suffer from pain, swelling, and organ damage. This medication represents a completely new approach: instead of just suppressing the immune system, it uses your own cells to help restore balance and stop the disease.
You likely qualify if…
You likely don't qualify if…
You will first receive two chemotherapy drugs (cyclophosphamide and fludarabine) to prepare your immune system for the new cells. Then, on day 0, you will receive an infusion of SCAR02 cells. After that, you will be monitored closely by the study team through follow-up visits and blood tests to track how well the treatment works and watch for any side effects. The study will take place at a single hospital in China, and your doctors will work with you to manage your care throughout the process.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China
Sponsor
The First Affiliated Hospital of University of Science and Technology of China
Enrollment target
~18 participants
Started
April 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
zhu chen, M.D
The First Affiliated Hospital of University of Science and Technology of China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.